DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

SECTION III
MODULATION OF CARDIOVASCULAR FUNCTION
812 Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of
the angiotensin converting enzyme inhibitor enalapril on the
long- term progression of left ventricular dysfunction in
patients with heart failure. Studies of Left Ventricular
Dysfunction (SOLVD) Investigators. Circulation, 1992,
86:431–438.
Krikler DM. The foxglove, “The old woman from Shropshire”
and William Withering. J Am Coll Cardiol, 1985, 5(A):3A–9A.
Kum LC, Yip GW, Lee PW, et al. Comparison of angiotensinconverting
enzyme inhibitor alone and in combination with
irbesartan for the treatment of heart failure. Int J Cardiol,
2008, 125:16–21.
Lahav M, Regev A, Ra’anani P, Theodor E. Intermittent administration
of furosemide versus continuous infusion preceded
by a loading dose for congestive heart failure. Chest, 1992,
102:725–731.
Lapp H, Mitrovic V, Franz N, et al. Cinaciguat (BAY 58-2667)
improves cardiopulmonary hemodynamics in patients with
acute decompensated heart failure. Circulation, 2009, 119:
2781–2788.
Leopold JA, Dam A, Maron BA, et al. Aldosterone impairs vascular
reactivity by decreasing glucose-6-phosphate dehydrogenase
activity. Nat Med, 2007, 13:189–197.
Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves
exercise hemodynamics and oxygen uptake in patients with
systolic heart failure. Circulation, 2007, 115:59–66.
Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme
A reductase inhibition beyond low- density lipoprotein
cholesterol. Am J Cardiol, 2005, 96:24F–33F.
Maron BA, Zhang YY, Handy DE, et al. Aldosterone increases
oxidant stress to impair guanylyl cyclase activity by cysteinyl
thiol oxidation in vascular smooth muscle cells. J Biol Chem,
2009, 284:7665–7672.
Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in
patients with heart failure and preserved ejection fraction.
N Engl J Med, 2008, 359:2456–2467.
McCurley JM, Hanlon SU, Wei SK, et al. Furosemide and the
progression of left ventricular dysfunction in experimental
heart failure. J Am Coll Cardiol, 2004, 44:1301–1307.
McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan,
enalapril, and their combination in congestive heart
failure: Randomized evaluation of strategies for left ventricular
dysfunction (RESOLVD) pilot study. The RESOLVD Pilot
Study Investigators. Circulation, 1999, 100:1056–1064.
McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan
in patients with chronic heart failure and reduced leftventricular
systolic function taking angiotensin- convertingenzyme
inhibitors: The CHARM- Added trial. Lancet, 2003,
362:767–771.
McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct
renin inhibitor aliskiren in patients with symptomatic heart
failure. Circ Heart Fail, 2008, 1:17–24.
MERIT- HF Study Group. Effect of metoprolol CR/XL in chronic
heart failure: Metoprolol CR/XL Randomised Intervention
Trial in Congestive Heart Failure (MERIT- HF). Lancet, 1999,
353:2001–2007.
Münzel T, Daiber A, Mülsch A. Explaining the phenomenon of
nitrate tolerance. Circ Res, 2005, 97:618–628.
Münzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents
nitroglycerin tolerance by inhibiting activation of a membranebound
NADH oxidase. A new action for an old drug. J Clin
Invest, 1996, 98:1465–1470.
Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol
on morbidity and mortality in patients with chronic heart failure.
U.S. Carvedilol Heart Failure Study Group. N Engl J Med,
1996, 334:1349–1355.
Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone
on mortality in severe chronic heart failure. PROMISE
Study Research Group. N Engl J Med, 1991, 325:1468–1475.
Packer M, Fowler MB, Roecker EB, et al. Carvedilol Prospective
Randomized Cumulative Survival (COPERNICUS) Study
Group. Effects of carvedilol on morbidity of patients with
severe chronic heart failure: Results of the carvedilol prospective
randomized cumulative survival (COPERNICUS) study.
Circulation, 2002, 106:2194–2199.
Packer M, Gheorghiade M, Young JB, et al. Withdrawal of
digoxin from patients with chronic heart failure treated with
angiotensin- converting- enzyme inhibitors. RADIANCE Study.
N Engl J Med, 1993, 329:1–7.
Packer M, Poole- Wilson PA, Armstrong PW, et al. Comparative
effects of low and high doses of the angiotensin converting
enzyme inhibitor, lisinopril, on morbidity and mortality in
chronic heart failure. Assessment of Treatment with Lisinopril
and Survival (ATLAS) Study Group. Circulation, 1999,
100:2312–2318.
Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on
mortality and morbidity in patients with left ventricular dysfunction
after myocardial infarction. Results of the Survival
And Ventricular Enlargement trial. The SAVE Investigators.
N Engl J Med, 1992, 327:669–677.
Pitt B, Remme W, Zannad F, et al., and the Eplerenone Post-
Acute Myocardial Infarction Heart Failure Efficacy and
Survival Study Investigators. Eplerenone, a selective aldosterone
blocker, in patients with left ventricular dysfunction
after myocardial infarction. N Engl J Med, 2003, 348:
1309–1321.
Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan
versus captopril in patients over 65 with heart failure
(Evaluation of Losartan in the Elderly Study, ELITE). Lancet,
1997, 349:747–752.
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone
on morbidity and mortality in patients with severe heart failure.
Randomized Aldactone Evaluation Study Investigators. N
Engl J Med, 1999, 341:709–717.
Sanoski CA. Aliskiren: An oral direct renin inhibitor for the treatment
of hypertension. Pharmacotherapy, 2009, 29:193–212.
Sawyer DB, Colucci WS. Mitochondrial oxidative stress in heart
failure: “Oxygen wastage” revisited. Circ Res, 2000, 86:
119–120.
Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the
direct renin inhibitor aliskiren, the angiotensin receptor
blocker losartan, or both on left ventricular mass in patients
with hypertension and left ventricular hypertrophy.
Circulation, 2009, 119:530–537.
Solomon SD, Janardhanan R, Verma A, et al. Effect of angiotensin
receptor blockade and antihypertensive drugs on diastolic function
in patients with hypertension and diastolic dysfunction: A
randomized trial. Lancet, 2007, 369:2079–2087.
St. John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative
two- dimensional echocardiographic measurements are major